Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products

88.3K

views

79

authors

12

articles

Editorial

09 December 2020

Editorial: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products

Ivan Martin

,

Yves Bayon

,

Tracy T. L. Yu

and

Alain A. Vertès

2,178 views

1 citations

Editors

4

Tracy Tong Li Yu

Merck Healthcare KGaA

Sofradim Production, A Medtronic Company

NxR Biotechnologies GmbH

University of Basel

Impact

About

Despite numerous breakthroughs in basic science, and continuous efforts to translate these discoveries into patients’ clinical benefits, only a handful of advanced therapy medicinal products (ATMPs) have been approved in the past decade. Among those approved, about a third have been pulled from the market and only few have reached appropriate commercial market penetration.

This Research Topic aims to discuss:
(1) key challenges that have hindered the successful translation and commercialisation of ATMPs,
(2) emerging concepts and incentives that fuel the up-and-coming novel ATMPs,
(3) learnings and new ideas that could boost more successes, and
(4) perspectives on key trends that highlight the medium-term evolution of the field of gene-based and cell-based therapies.

Dr. Yves Bayon is a Senior Principal Scientist at Medtronic and Dr. Alain Vertes is affiliated with NxR Biotechnologies GmbH. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

Despite numerous breakthroughs in basic science, and continuous efforts to translate these discoveries into patients’ clinical benefits, only a handful of advanced therapy medicinal products (ATMPs) have been approved in the past decade. Among those approved, about a third have been pulled from the market and only few have reached appropriate commercial market penetration.

This Research Topic aims to discuss:
(1) key challenges that have hindered the successful translation and commercialisation of ATMPs,
(2) emerging concepts and incentives that fuel the up-and-coming novel ATMPs,
(3) learnings and new ideas that could boost more successes, and
(4) perspectives on key trends that highlight the medium-term evolution of the field of gene-based and cell-based therapies.

Dr. Yves Bayon is a Senior Principal Scientist at Medtronic and Dr. Alain Vertes is affiliated with NxR Biotechnologies GmbH. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

Download ebook

Share

Editors

Tracy Tong Li Yu

Merck Healthcare KGaA

Sofradim Production, A Medtronic Company

NxR Biotechnologies GmbH

University of Basel

Impact

88,273 Total views

67,794 Article views

19,107 Article downloads

1,372 Topic views

Published In

Journal Thumbnail

Frontiers in Bioengineering and Biotechnology

Tissue Engineering and Regenerative Medicine

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic